Angelica Loskog | Chief Executive Officer
Lokon Pharma

Angelica Loskog, Chief Executive Officer, Lokon Pharma

Angelica Loskog is the CEO of Lokon Pharma and a Professor of immunotherapy at Uppsala University in Sweden. Further, she is a scientific advisor to the venture capital company Nexttobe AB and is a board member of several of their portfolio companies. Dr Loskog did her postdoc at Baylor College of Medicine, Texas, and her research focuses to develop immunostimulatory gene therapy of cancer utilizing oncolytic viruses, and gene engineering of CAR T cells.


Festival of Biologics Day 2 @ 17:40

Intratumoral immunostimulatory gene therapy in combination with chemotherapy for the treatment of pancreatic cancer

  • Patients diagnosed with pancreatic cancer have poor prognosis due to the therapy-resistant tumor including resistance to modern immunotherapies such as checkpoint blockade antibodies.
  • LOAd703 is a replication-restricted adenovirus encoding TMZ-CD40L and 4-1BBL under control of a CMV promoter with the capacity to genetically engineer the tumor and its stroma to cause inflammation
  • Clinical data will be presented demonstrating mechanisms-of-action, safety profile and efficacy such as response rate and overall survival in patients with pancreatic cancer treated with LOAd703 in combination with gemcitabine and nab-paclitaxel
last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers